We are pleased to announce that Exogenus Therapeutics has been granted another patent, now in Europe! This is the fifth region to recognize the patent family titled “Use of umbilical cord blood-derived exosomes for tissue repair.” This patent family has also been granted in Canada, China, Japan and Korea.
This invention leverages exosomes naturally released by umbilical cord blood cells, subjected to a specific pre-conditioning environment, and provides a therapeutic approach for regenerative medicine. Exogenus has thoroughly characterized these exosomes and their bioactivity, uncovering a multifactorial mechanism of action.
Our CEO, Joana Correia, also inventor of the patent, stated: “This new European patent is a significant achievement for Exogenus Therapeutics. It opens doors to a robust international market, strengthens our patent portfolio, and highlights our commitment to innovation.”
Exogenus Therapeutics‘ patent portfolio includes three families related to its lead product, Exo-101, covering different aspects of its composition, manufacturing process, and therapeutic applications (including inflammatory and fibrotic diseases).
As a leading exosome biotech company, Exogenus is dedicated to developing innovative, safe, and effective therapies for patients with significant unmet needs. The company now plans to broaden the applications of its proprietary exosomes to treat a diverse range of conditions involving tissue repair and control of inflammation.
Our patents can be accessed here:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017163132
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020070700&_cid=P11-LXLUZM-96523-1
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024105629